Dr. Haecker’s client list encompasses big pharma to emerging regenmed and stem cell based companies, investment banking and venture to academia. She has both published and spoken to a world-wide audience in the area of progressive, innovative stem cell science and specifically on business modeling in the ReGEN Industry. With postdoctoral training in the School of Medicine and Gene Therapy Program at the University of Pennsylvania, Sarah has a broad technical knowledge base in regenerative medicine, tissue engineering, stem cell biology and application, gene and cell therapy, translational research, and clinic applications.
Dan brings over 25 years of experience in the medical device industry with more than 12 of those years focused in the area of emerging stem cell therapies where he held various senior and executive management positions in sales, marketing, business development, and operations, with start-up, small, medium and Fortune 500 companies.
During the course of his career Dan has been responsible for strategic planning, business planning, launching new products into worldwide markets, building and managing international distribution channels, and identifying and establishing relationships with strategic partners.
As a former Pfizer scientist and founding member of their stem cell research unit overseeing global efforts in stem cell technologies as part of the Genetically Modified Models Center of Emphasis, Dr. John Hambor has over 20 years of research, management and training experience in both the pharmaceutical and biotechnology industries.
As a skilled
Copyright©2010 Vocus, Inc.
All rights reserved